

Francesco Panza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5850993/publications.pdf>

Version: 2024-02-01

411
papers

42,721
citations

9786

73
h-index

2747

192
g-index

419
all docs

419
docs citations

419
times ranked

55948
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver frailty and all-cause mortality in the older participants of the Salus in Apulia Study. <i>GeroScience</i> , 2022, 44, 835-845.	4.6	12
2	Role of plant-based diet in late-life cognitive decline: results from the Salus in Apulia Study. <i>Nutritional Neuroscience</i> , 2022, 25, 1300-1309.	3.1	15
3	Processed meat consumption and the risk of incident late-onset depression: a 12-year follow-up of the Salus in Apulia Study. <i>Age and Ageing</i> , 2022, 51, .	1.6	5
4	The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy. <i>Psychiatry Research</i> , 2022, 308, 114346.	3.3	3
5	Mediterranean Diet and Fatty Liver Risk in a Population of Overweight Older Italians: A Propensity Score-Matched Case-Cohort Study. <i>Nutrients</i> , 2022, 14, 258.	4.1	5
6	Frailty and outcome after traumatic brain injury. <i>Lancet Neurology</i> , The, 2022, 21, 107-108.	10.2	6
7	Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210816.	2.5	8
8	Association of Neuroretinal Thinning and Microvascular Changes with Hypertension in an Older Population in Southern Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1098.	2.4	6
9	Role of Dietary Carotenoids in Frailty Syndrome: A Systematic Review. <i>Biomedicines</i> , 2022, 10, 632.	3.2	7
10	Dietary Patterns Associated with Diabetes in an Older Population from Southern Italy Using an Unsupervised Learning Approach. <i>Sensors</i> , 2022, 22, 2193.	3.8	11
11	Dietary Customs and Social Deprivation in an Aging Population From Southern Italy: A Machine Learning Approach. <i>Frontiers in Nutrition</i> , 2022, 9, 811076.	3.7	6
12	Role of inflammatory markers in the diagnosis of vascular contributions to cognitive impairment and dementia: a systematic review and meta-analysis. <i>GeroScience</i> , 2022, 44, 1373-1392.	4.6	36
13	Clinical Indicators of Oral Frailty: A Domain-Specific Frailty Phenotype. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 2391-2394.	2.1	4
14	ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 759-771.	4.1	6
15	Motoric Cognitive Risk Syndrome, Subtypes and 8-Year All-Cause Mortality in Aging Phenotypes: The Salus in Apulia Study. <i>Brain Sciences</i> , 2022, 12, 861.	2.3	7
16	Coffee Drinking and Adverse Physical Outcomes in the Aging Adult Population: A Systematic Review. <i>Metabolites</i> , 2022, 12, 654.	2.9	4
17	Retinal Vascular Density on Optical Coherence Tomography Angiography and Age-Related Central and Peripheral Hearing Loss in a Southern Italian Older Population. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 2169-2177.	3.6	6
18	Late-life depression and its impact on rehabilitation after traumatic injuries. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 2313-2316.	2.9	2

#	ARTICLE	IF	CITATIONS
19	Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism. Expert Opinion on Pharmacotherapy, 2021, 22, 325-337.	1.8	2
20	Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy. GeroScience, 2021, 43, 1003-1014.	4.6	6
21	Oral frailty and neurodegeneration in Alzheimer's disease. Neural Regeneration Research, 2021, 16, 2149.	3.0	34
22	Vitamin D in the development and progression of Alzheimer's disease: implications for clinical management. Expert Review of Neurotherapeutics, 2021, 21, 287-301.	2.8	9
23	Cognitive frailty. , 2021, , 463-476.		2
24	How gait influences frailty models and health-related outcomes in clinical-based and population-based studies: a systematic review. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 274-297.	7.3	52
25	Physical Frailty, Multimorbidity, and All-Cause Mortality in an Older Population From Southern Italy: Results from the Salus in Apulia Study. Journal of the American Medical Directors Association, 2021, 22, 598-605.	2.5	53
26	Non Alcoholic Fatty Liver Disease Is Positively Associated with Increased Glycated Haemoglobin Levels in Subjects without Diabetes. Journal of Clinical Medicine, 2021, 10, 1695.	2.4	11
27	Dietary Habits and Nutrient Intakes Are Associated to Age-Related Central Auditory Processing Disorder in a Cohort From Southern Italy. Frontiers in Aging Neuroscience, 2021, 13, 629017.	3.4	4
28	Physical and cognitive profiles in motoric cognitive risk syndrome in an older population from Southern Italy. European Journal of Neurology, 2021, 28, 2565-2573.	3.3	23
29	Association Between Central and Peripheral Age-Related Hearing Loss and Different Frailty Phenotypes in an Older Population in Southern Italy. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 561.	2.2	31
30	Oral frailty and its determinants in older age: a systematic review. The Lancet Healthy Longevity, 2021, 2, e507-e520.	4.6	89
31	COVID-19 clinical phenotypes and short-term outcomes: differences between the first and the second wave of pandemic in Italy. Expert Review of Respiratory Medicine, 2021, 15, 1-7.	2.5	11
32	Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides. Neuroscience and Biobehavioral Reviews, 2021, 127, 193-211.	6.1	54
33	Cross-sectional and longitudinal associations between adherence to Mediterranean diet with physical performance and cognitive function in older adults: A systematic review and meta-analysis. Ageing Research Reviews, 2021, 70, 101395.	10.9	95
34	Associations between nutritional frailty and 8-year all-cause mortality in older adults: The Salus in Apulia Study. Journal of Internal Medicine, 2021, 290, 1071-1082.	6.0	31
35	How many frailties exist? "Authors' reply. The Lancet Healthy Longevity, 2021, 2, e616.	4.6	1
36	More skilled clinical management of COVID-19 patients modified mortality in an intermediate respiratory intensive care unit in Italy. Respiratory Research, 2021, 22, 16.	3.6	11

#	ARTICLE	IF	CITATIONS
37	Bilevel and continuous positive airway pressure and factors linked to all-cause mortality in COVID-19 patients in an intermediate respiratory intensive care unit in Italy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 853-857.	2.5	14
38	Beverages Consumption and Oral Health in the Aging Population: A Systematic Review. <i>Frontiers in Nutrition</i> , 2021, 8, 762383.	3.7	21
39	Consumption of processed meat may increase the risk of incident late-onset depression. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119225.	0.6	0
40	Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study. <i>Biomedicine</i> , 2021, 9, 1617.	3.2	2
41	Could epigenetics play a role in suicidal behavior in older age?. <i>Epigenomics</i> , 2021, , .	2.1	1
42	Retinal Vascular Density on OCT-A and Age-Related Central and Peripheral Hearing Loss in an Italian Older Population. <i>Innovation in Aging</i> , 2021, 5, 155-155.	0.1	0
43	Impact of Different Operational Definitions of Sarcopenia on Prevalence in a Population-Based Sample: The Salus in Apulia Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12979.	2.6	6
44	Liver Health and Dementia in an Italian Older Population: Findings From the Salus in Apulia Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 748888.	3.4	12
45	A family history of type 2 diabetes as a predictor of fatty liver disease in diabetes-free individuals with excessive body weight. <i>Scientific Reports</i> , 2021, 11, 24084.	3.3	9
46	National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. <i>International Journal of Epidemiology</i> , 2020, 49, 173-192.	1.9	44
47	Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 919-933.	4.1	22
48	Frontal lobe syndrome and dementias. , 2020, , 617-632.		1
49	Age-related hearing loss and neuropathologic burden. <i>Neurology</i> , 2020, 95, 511-512.	1.1	8
50	Anti-amyloid- β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 319-335.	2.4	57
51	Adherence to a Mediterranean Diet and Thyroid Function in Obesity: A Cross-Sectional Apulian Survey. <i>Nutrients</i> , 2020, 12, 3173.	4.1	18
52	Activity Energy Expenditure Predicts Clinical Average Levels of Physical Activity in Older Population: Results from Salus in Apulia Study. <i>Sensors</i> , 2020, 20, 4585.	3.8	11
53	Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12065.	3.7	21
54	Nutritional domains in frailty tools: Working towards an operational definition of nutritional frailty. <i>Ageing Research Reviews</i> , 2020, 64, 101148.	10.9	43

#	ARTICLE	IF	CITATIONS
55	Age-related hearing loss and speech perception disorder: the broken interface between healthcare professionals and older adults. <i>European Geriatric Medicine</i> , 2020, 11, 893-895.	2.8	4
56	The relationship between epigenetics and microbiota in neuropsychiatric diseases. <i>Epigenomics</i> , 2020, 12, 1559-1568.	2.1	11
57	A multidimensional frailty approach in predicting and preventing dementia. <i>The Lancet Healthy Longevity</i> , 2020, 1, e49-e50.	4.6	3
58	Social Frailty in the COVID-19 Pandemic Era. <i>Frontiers in Psychiatry</i> , 2020, 11, 577113.	2.6	20
59	Can pharmacotherapy effectively reduce Alzheimer's related agitation?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1517-1522.	1.8	4
60	Social determinants of late-life depression epigenetics. <i>Epigenomics</i> , 2020, 12, 559-562.	2.1	10
61	Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 213-228.	10.1	73
62	Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia Study. <i>Nutrients</i> , 2020, 12, 426.	4.1	40
63	Traditional Dietary Patterns and Risk of Mortality in a Longitudinal Cohort of the Salus in Apulia Study. <i>Nutrients</i> , 2020, 12, 1070.	4.1	27
64	Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts. <i>Clinical Neurophysiology</i> , 2020, 131, 1287-1310.	1.5	123
65	The association of patient-reported symptoms and clinical and lung function parameters in patients with chronic obstructive pulmonary disease in stable phase. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 637-643.	2.5	2
66	Age-Related Central Auditory Processing Disorder, MCI, and Dementia in an Older Population of Southern Italy. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 348-355.	1.9	39
67	Disproportionate Impairment in Naming and Comprehension of Nouns with Relative Sparing of Verbs in a Patient who Survived Herpes Simplex Encephalitis. <i>International Journal of Speech & Language Pathology and Audiology</i> , 2020, 8, 29-37.	0.2	2
68	ORO-Dental Manifestations in West Syndrome. <i>Current Topics in Medicinal Chemistry</i> , 2020, 19, 2824-2828.	2.1	7
69	The Challenge of Antidepressant Therapeutics in Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1260, 267-281.	1.6	4
70	Delusions in dementias. , 2020, , 647-664.		0
71	Klotho at the Edge of Alzheimer's Disease and Senile Depression. <i>Molecular Neurobiology</i> , 2019, 56, 1908-1920.	4.0	26
72	Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. <i>Lancet, The</i> , 2019, 394, 639-651.	13.7	325

#	ARTICLE	IF	CITATIONS
73	Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging. <i>Alzheimer's and Dementia</i> , 2019, 15, 1019-1028.	0.8	47
74	Time to test antibacterial therapy in Alzheimer's disease. <i>Brain</i> , 2019, 142, 2905-2929.	7.6	89
75	Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 751-765.	3.3	0
76	Do anti-amyloid- β^2 drugs affect neuropsychiatric status in Alzheimer's disease patients?. <i>Ageing Research Reviews</i> , 2019, 55, 100948.	10.9	24
77	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimer's disease. <i>Translational Psychiatry</i> , 2019, 9, 55.	4.8	32
78	Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 599-602.	2.8	32
79	The Age-Related Central Auditory Processing Disorder: Silent Impairment of the Cognitive Ear. <i>Frontiers in Neuroscience</i> , 2019, 13, 619.	2.8	70
80	Rising rural body-mass index is the main driver of the global obesity epidemic in adults. <i>Nature</i> , 2019, 569, 260-264.	27.8	469
81	Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1091-1107.	1.8	15
82	Episodic memory and learning rates in amyotrophic lateral sclerosis without dementia. <i>Cortex</i> , 2019, 117, 257-265.	2.4	9
83	Disease-modifying therapies for tauopathies: agents in the pipeline. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 397-408.	2.8	15
84	Hydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2019, 8, 4.	8.0	5
85	The Role of Biomarkers in Psychiatry. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1118, 135-162.	1.6	29
86	Power Doppler Ultrasound Findings before and after Focused Extracorporeal Shock Wave Therapy for Achilles Tendinopathy: A Pilot Study on Pain Reduction and Neovascularization Effect. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 1316-1323.	1.5	20
87	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates $A\beta^2$, tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
88	Multiple personality and hallucinations in a patient with normal dat-scan spect fulfilling diagnostic criteria for probable dementia with lewy bodies. <i>Journal of the Neurological Sciences</i> , 2019, 405, 120.	0.6	0
89	A critical appraisal of amyloid- β^2 -targeting therapies for Alzheimer's disease. <i>Nature Reviews Neurology</i> , 2019, 15, 73-88.	10.1	666
90	Are antibodies directed against amyloid- β^2 ($A\beta^2$) oligomers the last call for the $A\beta^2$ hypothesis of Alzheimer's disease?. <i>Immunotherapy</i> , 2019, 11, 3-6.	2.0	50

#	ARTICLE	IF	CITATIONS
91	Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231881100.	2.5	68
92	Response to Letter to the Editor: "Plasma β -amyloid β 42 reference values". <i>Journal of the Neurological Sciences</i> , 2019, 396, 123-124.	0.6	0
93	Understanding frailty to predict and prevent dementia. <i>Lancet Neurology</i> , The, 2019, 18, 133-134.	10.2	19
94	Amyloid β immunotherapy for alzheimer disease: Is it now a long shot?. <i>Annals of Neurology</i> , 2019, 85, 303-315.	5.3	126
95	Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke. <i>Drugs</i> , 2019, 79, 143-160.	10.9	38
96	Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 4333-4344.	4.0	19
97	Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer's Disease Versus Vascular Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 699-711.	2.6	17
98	Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 993-1012.	2.6	214
99	Comprehensive Geriatric Assessment in Long-Term Care and Nursing Homes. <i>Practical Issues in Geriatrics</i> , 2018, , 47-56.	0.8	0
100	Pharmacotherapy for the treatment of depression in patients with alzheimer's disease: a treatment-resistant depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 823-842.	1.8	43
101	Genetics of tailored medicine: Focus on CNS drugs. <i>Microchemical Journal</i> , 2018, 136, 164-169.	4.5	1
102	An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-Term Care Facilities. <i>Rejuvenation Research</i> , 2018, 21, 3-14.	1.8	25
103	Association of Antidementia Drugs and Mortality in Community-Dwelling Frail Older Patients With Dementia: The Role of Mortality Risk Assessment. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 162-168.	2.5	18
104	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 25-35.	3.1	34
105	Can a cognitive rehabilitation program in early stages of Parkinson's disease improve cognition, apathy and brain functional connectivity for up to 18 months?. <i>European Journal of Neurology</i> , 2018, 25, 203-204.	3.3	3
106	Sensory Changes and the Hearing Loss "Cognition Link. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 127.	2.2	16
107	CYP2D6 genotypes in revolving door patients with bipolar disorders. <i>Medicine (United States)</i> , 2018, 97, e11998.	1.0	26
108	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 847-857.	2.8	66

#	ARTICLE	IF	CITATIONS
109	Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 95, 480-498.	6.1	27
110	Apathy and depressive symptoms in older people and incident myocardial infarction, stroke, and mortality: a systematic review and meta-analysis of individual participant data. <i>Clinical Epidemiology</i> , 2018, Volume 10, 363-379.	3.0	49
111	Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 989-1000.	2.6	42
112	Plasma β -amyloid 1 α 42 reference values in cognitively normal subjects. <i>Journal of the Neurological Sciences</i> , 2018, 391, 120-126.	0.6	19
113	Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S229-S254.	2.6	38
114	Contribution of Mediterranean Diet in the Prevention of Alzheimer's Disease. , 2018, , 139-155.		3
115	Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder. <i>Molecular Neurobiology</i> , 2017, 54, 1340-1351.	4.0	28
116	Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy. <i>Alzheimer's and Dementia</i> , 2017, 13, 858-869.	0.8	24
117	Emerging biomarkers and screening for cognitive frailty. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 1075-1086.	2.9	39
118	Long-term safety of repeated high doses of onabotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke. <i>Journal of the Neurological Sciences</i> , 2017, 378, 182-186.	0.6	18
119	Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 121-130.	2.6	41
120	Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 89.e1-89.e8.	2.5	126
121	Anti-tau vaccine in Alzheimer's disease: a tentative step. <i>Lancet Neurology</i> , The, 2017, 16, 99-100.	10.2	10
122	Three Decades of Comprehensive Geriatric Assessment: Evidence Coming From Different Healthcare Settings and Specific Clinical Conditions. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 192.e1-192.e11.	2.5	277
123	Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 815-849.	2.6	249
124	Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. <i>Lancet</i> , The, 2017, 390, 2627-2642.	13.7	5,010
125	Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1373-1385.	2.4	8
126	Information and Communication Technologies for the Activities of Daily Living in Older Patients with Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 927-935.	2.6	60

#	ARTICLE	IF	CITATIONS
127	Cognitive frailty: a potential target for secondary prevention of dementia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1023-1027.	3.3	40
128	Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry. Expert Review of Proteomics, 2017, 14, 809-824.	3.0	36
129	Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity. Drugs, 2017, 77, 1413-1422.	10.9	7
130	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
131	Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging. American Journal of Geriatric Psychiatry, 2017, 25, 1236-1248.	1.2	90
132	Change in Coefficient of Fatigability Following Rapid, Repetitive Movement Training in Post-Stroke Spastic Paresis: A Prospective Open-Label Observational Study. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 2536-2540.	1.6	17
133	Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet, The, 2017, 389, 37-55.	13.7	1,667
134	Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 259-277.	3.3	13
135	Evaluation of endothelial function and cardiovascular risk in non-obese patients with slight degree of obstructive sleep apnea syndrome. Monaldi Archives for Chest Disease, 2017, 87, 822.	0.6	4
136	Phytochemicals in the Treatment of Alzheimer's Disease: A Systematic Review. Current Drug Targets, 2017, 18, 1487-1498.	2.1	38
137	Sensory impairments and cognitive disorders in older age. Geriatric Care, 2017, 3, .	0.2	0
138	Comprehensive geriatric assessment: evidence. , 2017, , 117-126.		6
139	Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. BioMed Research International, 2016, 2016, 1-15.	1.9	138
140	Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease. Parkinson's Disease, 2016, 2016, 1-14.	1.1	13
141	Warfarin Treatment and All-Cause Mortality in Community-Dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study. Journal of the American Geriatrics Society, 2016, 64, 1416-1424.	2.6	35
142	Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. Expert Review of Neurotherapeutics, 2016, 16, 1357-1369.	2.8	10
143	Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study. European Journal of Neurology, 2016, 23, 1117-1125.	3.3	19
144	Delusions in Patients with Alzheimer's Disease: A Multidimensional Approach. Journal of Alzheimer's Disease, 2016, 51, 427-437.	2.6	26

#	ARTICLE	IF	CITATIONS
145	Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?. International Psychogeriatrics, 2016, 28, 1111-1124.	1.0	19
146	Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association. Journal of Alzheimer's Disease, 2016, 55, 973-979.	2.6	23
147	Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4Â4 million participants. Lancet, The, 2016, 387, 1513-1530.	13.7	2,842
148	Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19Â2 million participants. Lancet, The, 2016, 387, 1377-1396.	13.7	3,941
149	Relation of Statin Use and Mortality in Community-Dwelling Frail Older Patients With Coronary Artery Disease. American Journal of Cardiology, 2016, 118, 1624-1630.	1.6	52
150	Emerging drugs to reduce abnormal Î²-amyloid protein in Alzheimerâ€™s disease patients. Expert Opinion on Emerging Drugs, 2016, 21, 377-391.	2.4	54
151	Is Extracorporeal Shockwave Therapy Combined With Isokinetic Exercise More Effective Than Extracorporeal Shockwave Therapy Alone for Subacromial Impingement Syndrome? A Randomized Clinical Trial. Journal of Orthopaedic and Sports Physical Therapy, 2016, 46, 714-725.	3.5	21
152	Tau-based therapeutics for Alzheimerâ€™s disease: active and passive immunotherapy. Immunotherapy, 2016, 8, 1119-1134.	2.0	61
153	Pharmacogenetics in Neurodegenerative Diseases: Implications for Clinical Trials. Frontiers of Neurology and Neuroscience, 2016, 39, 124-135.	2.8	4
154	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
155	A Validation Study of Vascular Cognitive Impairment Genetics Meta-Analysis Findings in an Independent Collaborative Cohort. Journal of Alzheimer's Disease, 2016, 53, 981-989.	2.6	22
156	Daily Function as Predictor of Dementia in Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI): An 8-Year Follow-Up in the ILSA Study. Journal of Alzheimer's Disease, 2016, 53, 505-515.	2.6	27
157	The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes. Expert Review of Precision Medicine and Drug Development, 2016, 1, 431-442.	0.7	6
158	High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 843-846.	3.3	10
159	The Role of Hearing Impairment in Cognitive Decline: Need for the Special Sense Assessment in Evaluating Cognition In Older Age. Neuroepidemiology, 2016, 46, 290-291.	2.3	8
160	Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1069-1077.	2.5	52
161	Tau-directed approaches for the treatment of Alzheimerâ€™s disease: focus on leuco-methylthioninium. Expert Review of Neurotherapeutics, 2016, 16, 259-277.	2.8	35
162	Tau aggregation inhibitors: the future of Alzheimerâ€™s pharmacotherapy?. Expert Opinion on Pharmacotherapy, 2016, 17, 457-461.	1.8	17

#	ARTICLE	IF	CITATIONS
163	Time to generalisation as a predictor of prognosis in amyotrophic lateral sclerosis: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 678-679.	1.9	15
164	Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype. Journal of Alzheimer's Disease, 2015, 47, 793-813.	2.6	108
165	Coffee Consumption Habits and the Risk ofÂMild Cognitive Impairment: The Italian Longitudinal Study on Aging. Journal of Alzheimer's Disease, 2015, 47, 889-899.	2.6	51
166	Alternative pharmacological treatment options for agitation in Alzheimerâ€™s disease. Geriatric Care, 2015, 1, .	0.2	1
167	Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. Toxins, 2015, 7, 3045-3056.	3.4	33
168	Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanisms. Frontiers in Aging Neuroscience, 2015, 7, 113.	3.4	67
169	Postural and Balance Disorders in Patients with Parkinsonâ€™s Disease: A Prospective Open-Label Feasibility Study with Two Months of Action Observation Treatment. Parkinson's Disease, 2015, 2015, 1-7.	1.1	11
170	Measuring pharmacogenetics in special groups: geriatrics. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1073-1088.	3.3	23
171	Role of CYP2D6 Polymorphisms in the Outcome of Postoperative Pain Treatment. Pain Medicine, 2015, 16, 2012-2023.	1.9	12
172	Frontal assessment battery for detecting executive dysfunction in amyotrophic lateral sclerosis without dementia: a retrospective observational study. BMJ Open, 2015, 5, e007069.	1.9	25
173	A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 2015, 30, 965-975.	2.7	34
174	Epidemiology of age related hearing loss: A review. Hearing, Balance and Communication, 2015, 13, 77-81.	0.4	20
175	Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke. Journal of the Neurological Sciences, 2015, 350, 1-6.	0.6	42
176	Age-related hearing impairmentâ€™a risk factor and frailty marker for dementia and AD. Nature Reviews Neurology, 2015, 11, 166-175.	10.1	192
177	Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331â€™288 participants. Lancet Diabetes and Endocrinology,the, 2015, 3, 624-637.	11.4	139
178	Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis. Journal of Neurology, 2015, 262, 593-603.	3.6	56
179	Cognitive Frailty: A Systematic Review of Epidemiological and Neurobiological Evidence of an Age-Related Clinical Condition. Rejuvenation Research, 2015, 18, 389-412.	1.8	112
180	Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life. Journal of Psychopharmacology, 2015, 29, 623-633.	4.0	18

#	ARTICLE	IF	CITATIONS
181	Progresses in treating agitation: a major clinical challenge in Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2015, 16, 2581-2588.	1.8	43
182	Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: A systematic review. Journal of Nutrition, Health and Aging, 2015, 19, 313-328.	3.3	154
183	Caregiver burden characterization in patients with Alzheimer's disease or vascular dementia. International Journal of Geriatric Psychiatry, 2015, 30, 891-899.	2.7	61
184	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
185	Adhesive taping vs. daily manual muscle stretching and splinting after botulinum toxin type A injection for wrist and fingers spastic overactivity in stroke patients: a randomized controlled trial. Clinical Rehabilitation, 2015, 29, 50-58.	2.2	32
186	Statin Treatment and Mortality in Community-Dwelling Frail Older Patients with Diabetes Mellitus: A Retrospective Observational Study. PLoS ONE, 2015, 10, e0130946.	2.5	41
187	Nutrition, frailty, and Alzheimer's disease. Frontiers in Aging Neuroscience, 2014, 6, 221.	3.4	16
188	Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. Expert Review of Neurotherapeutics, 2014, 14, 973-986.	2.8	42
189	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Review of Clinical Immunology, 2014, 10, 405-419.	3.0	86
190	Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques. Journal of the Neurological Sciences, 2014, 347, 39-43.	0.6	47
191	Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. Current Opinion in Psychiatry, 2014, 27, 128-137.	6.3	86
192	Possible role of alpha-lipoic acid in the treatment of peripheral nerve injuries. Journal of Brachial Plexus and Peripheral Nerve Injury, 2014, 05, e1-e2.	1.0	9
193	Extracorporeal Shock Wave Therapy for the Treatment of Poststroke Plantar-Flexor Muscles Spasticity: A Prospective Open-Label Study. Topics in Stroke Rehabilitation, 2014, 21, S17-S24.	1.9	46
194	Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?. Expert Opinion on Biological Therapy, 2014, 14, 1465-1476.	3.1	63
195	Prevention of Late-life Cognitive Disorders: Diet-Related Factors, Dietary Patterns, and Frailty Models. Current Nutrition Reports, 2014, 3, 110-129.	4.3	9
196	An intrinsically safe facility for forefront research and training on nuclear technologies – A zero-power experiment. European Physical Journal Plus, 2014, 129, 1.	2.6	0
197	Prevalence of diabetes and depressive symptomatology and their effect on mortality risk in elderly Italians: The Italian Longitudinal Study on Aging. Diabetes and Metabolism, 2014, 40, 373-378.	2.9	12
198	Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes and Endocrinology, 2014, 2, 634-647.	11.4	591

#	ARTICLE	IF	CITATIONS
199	Plant-Based Nutraceutical Interventions against Cognitive Impairment and Dementia: Meta-Analytic Evidence of Efficacy of a Standardized Ginkgo biloba Extract. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 605-611.	2.6	28
200	Mediterranean Diet and Cognitive Decline. A Lesson from the Whole-Diet Approach: What Challenges Lie Ahead?. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 283-286.	2.6	48
201	Perspective: The Challenge of Clinical Decision-Making for Drug Treatment in Older People. The Role of Multidimensional Assessment and Prognosis. <i>Frontiers in Medicine</i> , 2014, 1, 61.	2.6	13
202	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e94661.	2.5	155
203	Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. <i>Age</i> , 2013, 35, 441-453.	3.0	35
204	Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. <i>Journal of Neural Transmission</i> , 2013, 120, 469-476.	2.8	32
205	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013, 45, 1452-1458.	21.4	3,741
206	SBOTE Study: Extracorporeal Shock Wave Therapy Versus Electrical Stimulation After Botulinum Toxin Type A Injection for Post-Stroke Spasticityâ€”A Prospective Randomized Trial. <i>Ultrasound in Medicine and Biology</i> , 2013, 39, 283-291.	1.5	61
207	Vascular factors predict polyneuropathy in a non-diabetic elderly population. <i>Neurological Sciences</i> , 2013, 34, 955-962.	1.9	13
208	Neutron flux characterization of the SM1 sub-critical multiplying complex of the Pavia University. <i>Progress in Nuclear Energy</i> , 2013, 67, 98-103.	2.9	11
209	Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging. <i>Alzheimer's and Dementia</i> , 2013, 9, 113-122.	0.8	140
210	The Serotonin Transporter Gene Locus in Late-Life Major Depressive Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 67-77.	1.2	8
211	Incidence of dementia: evidence for an effect modification by gender. The ILSA Study. <i>International Psychogeriatrics</i> , 2013, 25, 1867-1876.	1.0	24
212	Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. <i>Molecular Psychiatry</i> , 2013, 18, 461-470.	7.9	103
213	Neuropsychiatric Symptoms and Functional Status in Alzheimerâ€™s Disease and Vascular Dementia Patients. <i>Current Alzheimer Research</i> , 2012, 9, 759-771.	1.4	75
214	Addition of the Multidimensional Prognostic Index to the Estimated Glomerular Filtration Rate Improves Prediction of Long-Term All-Cause Mortality in Older Patients with Chronic Kidney Disease. <i>Rejuvenation Research</i> , 2012, 15, 82-88.	1.8	43
215	Immunotherapy for Alzheimerâ€™s disease: from anti-Î²-amyloid to tau-based immunization strategies. <i>Immunotherapy</i> , 2012, 4, 213-238.	2.0	121
216	A Multidimensional Prognostic Index in Common Conditions Leading to Death in Older Patients. <i>Archives of Internal Medicine</i> , 2012, 172, 594; discussion 594-5.	3.8	18

#	ARTICLE	IF	CITATIONS
217	Changes in severity of depressive symptoms and mortality: the Italian Longitudinal Study on Aging. <i>Psychological Medicine</i> , 2012, 42, 2619-2629.	4.5	16
218	Treatment of Upper Limb Spasticity after Stroke: One-Year Safety and Efficacy of Botulinum Toxin Type A NT201. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 57-62.	2.1	6
219	Treatment of Late-Life Major Depressive Disorder With Selective Serotonin Reuptake Inhibitors Improves the Multidimensional Prognostic Index. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 726-729.	1.4	20
220	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer's disease patients. <i>Future Neurology</i> , 2012, 7, 395-401.	0.5	1
221	Advances in the identification of β -secretase inhibitors for the treatment of Alzheimer's disease. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 19-37.	5.0	45
222	Klotho locus, metabolic traits, and serum hemoglobin in hospitalized older patients: a genetic association analysis. <i>Age</i> , 2012, 34, 949-968.	3.0	8
223	Effectiveness of the Frequency Rhythmic Electrical Modulation System for the Treatment of Chronic and Painful Venous Leg Ulcers in Older Adults. <i>Rejuvenation Research</i> , 2012, 15, 281-287.	1.8	26
224	TOMM40, APOE, and APOC1 in Primary Progressive Aphasia and Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 731-740.	2.6	20
225	Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease. <i>Ageing Research Reviews</i> , 2012, 11, 87-103.	10.9	57
226	Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 135-149.	3.0	79
227	Current Epidemiological Approaches to the Metabolic-Cognitive Syndrome. <i>Journal of Alzheimer's Disease</i> , 2012, 30, S31-S75.	2.6	44
228	Comparing the Prognostic Accuracy for All-Cause Mortality of Frailty Instruments: A Multicentre 1-Year Follow-Up in Hospitalized Older Patients. <i>PLoS ONE</i> , 2012, 7, e29090.	2.5	161
229	Effectiveness of Switching Therapy from Complexing Protein-containing Botulinum Toxin Type A to a Formulation with Low Immunogenicity in Spasticity after Stroke: A case report. <i>Journal of Rehabilitation Medicine</i> , 2012, 44, 795-797.	1.1	15
230	Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective?. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 1218-1238.	2.7	90
231	Frailty syndrome and all-cause mortality in demented patients: the Italian Longitudinal Study on Aging. <i>Age</i> , 2012, 34, 507-517.	3.0	51
232	A Multidimensional Prognostic Index (MPI) based on a comprehensive geriatric assessment predicts short- and long-term all-cause mortality in older hospitalized patients with transient ischemic attack. <i>Journal of Neurology</i> , 2012, 259, 670-678.	3.6	46
233	Metabolic syndrome as a risk factor for neurological disorders. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 741-762.	5.4	164
234	Usefulness of the multidimensional prognostic index (MPI) in the management of older patients with chronic kidney disease. <i>Journal of Nephrology</i> , 2012, 25, 79-84.	2.0	16

#	ARTICLE	IF	CITATIONS
235	The Serotonin Transporter Gene Locus in Late-Life Major Depressive Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2012, , 1.	1.2	0
236	Genetic variation in MME in relation to neprilysin protein and enzyme activity, A β levels, and Alzheimer's disease risk. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2012, 3, 30-8.	0.4	13
237	Monoclonal antibodies against β -amyloid (A β) for the treatment of Alzheimer's disease: the A β target at a crossroads. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 679-686.	3.1	40
238	Late-life depression and Alzheimer's disease: The glutamatergic system inside of this mirror relationship. <i>Brain Research Reviews</i> , 2011, 67, 344-355.	9.0	34
239	Therapeutic intervention for Alzheimer's disease with β -secretase inhibitors: still a viable option?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 325-341.	4.1	86
240	The Genetics of the Human APOE Polymorphism. <i>Rejuvenation Research</i> , 2011, 14, 491-500.	1.8	81
241	Diet and Alzheimer's disease risk factors or prevention: the current evidence. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 677-708.	2.8	231
242	Glycerophospholipids and glycerophospholipid-derived lipid mediators: A complex meshwork in Alzheimer's disease pathology. <i>Progress in Lipid Research</i> , 2011, 50, 313-330.	11.6	172
243	Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging. <i>Neurobiology of Aging</i> , 2011, 32, 1932-1941.	3.1	108
244	Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. <i>Neurobiology of Aging</i> , 2011, 32, 756.e11-756.e15.	3.1	82
245	Neuropsychiatric Symptoms, Endophenotypes, and Syndromes in Late-Onset Alzheimer's Disease: Focus on APOE Gene. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-14.	2.0	18
246	Pharmacogenetics in Geriatric Medicine: Challenges and Opportunities for Clinical Practice. <i>Current Drug Metabolism</i> , 2011, 12, 621-634.	1.2	17
247	Mediterranean Diet in Predementia and Dementia Syndromes. <i>Current Alzheimer Research</i> , 2011, 8, 520-542.	1.4	73
248	The APOE Gene Locus in Frontotemporal Dementia and Primary Progressive Aphasia. <i>Archives of Neurology</i> , 2011, 68, 622-8.	4.5	25
249	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 429-435.	21.4	1,708
250	APOE and Alzheimer disease: a major gene with semi-dominant inheritance. <i>Molecular Psychiatry</i> , 2011, 16, 903-907.	7.9	529
251	Effect of botulinum toxin type A and modified constraint-induced movement therapy on motor function of upper limb in children with obstetrical brachial plexus palsy. <i>Child's Nervous System</i> , 2011, 27, 2187-2192.	1.1	26
252	Different models of frailty in predementia and dementia syndromes. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 711-719.	3.3	76

#	ARTICLE	IF	CITATIONS
253	Angiotensin-converting enzyme (ACE) genotypes and disability in hospitalized older patients. Age, 2011, 33, 409-419.	3.0	6
254	The APOE polymorphism in Alzheimer's disease patients with neuropsychiatric symptoms and syndromes. International Journal of Geriatric Psychiatry, 2011, 26, 1062-1070.	2.7	27
255	Metabolic Syndrome, Mild Cognitive Impairment and Dementia. Current Alzheimer Research, 2011, 8, 492-509.	1.4	67
256	Anti- β -Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab. Current Alzheimer Research, 2011, 8, 808-817.	1.4	51
257	Interacting with γ -Secretase for Treating Alzheimer's Disease: From Inhibition to Modulation. Current Medicinal Chemistry, 2011, 18, 5430-5447.	2.4	26
258	Aluminium in the Diet, Cognitive Decline and Dementia. , 2011, , 2829-2850.		0
259	Alcohol Consumption in Predementia and Dementia Syndromes. , 2011, , 3011-3044.		0
260	Dietary Fatty Acids, Cognitive Decline, and Dementia. , 2011, , 2851-2883.		0
261	Metabolic Syndrome and Cognitive Impairment: Current Epidemiology and Possible Underlying Mechanisms. Journal of Alzheimer's Disease, 2010, 21, 691-724.	2.6	139
262	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. Journal of Alzheimer's Disease, 2010, 22, 247-255.	2.6	54
263	Aluminum in the Diet and Alzheimer's Disease: From Current Epidemiology to Possible Disease-Modifying Treatment. Journal of Alzheimer's Disease, 2010, 20, 17-30.	2.6	78
264	Nutraceutical Properties of Mediterranean Diet and Cognitive Decline: Possible Underlying Mechanisms. Journal of Alzheimer's Disease, 2010, 22, 715-740.	2.6	149
265	Peripheral Antioxidant Markers in Mild Cognitive Impairment and its Progression to Dementia. Journal of Alzheimer's Disease, 2010, 21, 1179-1183.	2.6	6
266	Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease. Journal of Neurology, 2010, 257, 139-141.	3.6	18
267	Apolipoprotein E-related all-cause mortality in hospitalized elderly patients. Age, 2010, 32, 411-420.	3.0	5
268	EFFECT OF DONEPEZIL ON THE CONTINUUM OF DEPRESSIVE SYMPTOMS, MILD COGNITIVE IMPAIRMENT, AND PROGRESSION TO DEMENTIA. Journal of the American Geriatrics Society, 2010, 58, 389-390.	2.6	6
269	PLASMA LEVELS OF ω 3 POLYUNSATURATED FATTY ACIDS AND COGNITIVE DECLINE: POSSIBLE ROLE OF DEPRESSIVE SYMPTOMS AND APOLIPOPROTEIN E GENOTYPING. Journal of the American Geriatrics Society, 2010, 58, 2249-2251.	2.6	4
270	PLASMA LIPID DISTURBANCES AND COGNITIVE DECLINE. Journal of the American Geriatrics Society, 2010, 58, 2429-2430.	2.6	20

#	ARTICLE	IF	CITATIONS
271	Alcohol consumption and metabolic syndrome in the elderly: results from the Italian longitudinal study on aging. <i>European Journal of Clinical Nutrition</i> , 2010, 64, 297-307.	2.9	46
272	Dietary Unsaturated Fatty Acids and Risk of Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 867-870.	2.6	12
273	Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?. <i>Frontiers in Aging Neuroscience</i> , 2010, 2, .	3.4	119
274	Polymorphism C in the Serotonin Transporter Gene in Depression-Free Elderly Patients with Vascular Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 424-431.	1.5	6
275	Effect of intrathecal baclofen, botulinum toxin type A and a rehabilitation programme on locomotor function after spinal cord injury: A case report. <i>Journal of Rehabilitation Medicine</i> , 2010, 42, 891-894.	1.1	12
276	Dietary Patterns and Protection Against Alzheimer Disease and Cognitive Decline. <i>Archives of Neurology</i> , 2010, 67, 1285.	4.5	5
277	Effect of botulinum toxin type A, motor imagery and motor observation on motor function of hemiparetic upper limb after stroke. <i>Brain Injury</i> , 2010, 24, 1108-1112.	1.2	12
278	Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 433-440.	1.9	100
279	Bapineuzumab: anti- β -amyloid monoclonal antibodies for the treatment of Alzheimer's disease. <i>Immunotherapy</i> , 2010, 2, 767-782.	2.0	52
280	Towards Disease-Modifying Treatment of Alzheimer's Disease: Drugs Targeting β -Amyloid. <i>Current Alzheimer Research</i> , 2010, 7, 40-55.	1.4	109
281	Late-Life Depression, Mild Cognitive Impairment, and Dementia: Possible Continuum?. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 98-116.	1.2	502
282	Polymorphisms in Glutathione S-Transferase Omega-1 Gene and Increased Risk of Sporadic Alzheimer Disease. <i>Rejuvenation Research</i> , 2010, 13, 645-652.	1.8	23
283	Effectiveness of botulinum toxin type A treatment of neck pain related to nocturnal bruxism: a case report. <i>Journal of Chiropractic Medicine</i> , 2010, 9, 132-137.	0.7	13
284	Interleukin β 174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 177-182.	4.8	27
285	Alcohol consumption and cardiovascular risk factors in older lifelong wine drinkers: The Italian Longitudinal Study on Aging. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 647-655.	2.6	52
286	Dietary fatty acids in dementia and predementia syndromes: Epidemiological evidence and possible underlying mechanisms. <i>Ageing Research Reviews</i> , 2010, 9, 184-199.	10.9	112
287	Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease. <i>Ageing Research Reviews</i> , 2010, 9, 399-417.	10.9	292
288	Pharmacogenetics of cytochrome P450 (CYP) in the elderly. <i>Ageing Research Reviews</i> , 2010, 9, 457-474.	10.9	53

#	ARTICLE	IF	CITATIONS
289	REVIEW: Î³â€Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State. CNS Neuroscience and Therapeutics, 2010, 16, 272-284.	3.9	63
290	Is Insulin Resistant Brain State a Central Feature of the Metabolic-Cognitive Syndrome?. Journal of Alzheimer's Disease, 2010, 21, 57-63.	2.6	69
291	Prevalence of Aging-Associated Cognitive Decline in an Italian elderly population: results from cross-sectional phase of Italian PProject on Epidemiology of Alzheimerâ€™s disease (IPREA). Aging Clinical and Experimental Research, 2010, 22, 440-449.	2.9	22
292	Aluminum in the diet and Alzheimer's disease: from current epidemiology to possible disease-modifying treatment. Journal of Alzheimer's Disease, 2010, 20, 17-30.	2.6	42
293	LRP-1 variation is not associated with risk of Alzheimer's disease. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 104-13.	0.4	8
294	Cognitive behavioural group therapy in mild cognitive impairment: Intervention with a cognitive or behavioural/psychological focus?. Journal of Rehabilitation Medicine, 2009, 41, 293-294.	1.1	1
295	Polyunsaturated Fatty Acid and S-Adenosylmethionine Supplementation in Predementia Syndromes and Alzheimer's Disease: A Review. Scientific World Journal, The, 2009, 9, 373-389.	2.1	24
296	Dietary Fatty Acids and Predementia Syndromes. Scientific World Journal, The, 2009, 9, 792-810.	2.1	10
297	All-Cause Mortality and Competing Risks of Fatal and Nonfatal Vascular Events in the Italian Longitudinal Study on Aging: Impact of Lipoprotein(a). Rejuvenation Research, 2009, 12, 395-402.	1.8	4
298	Mediterranean Dietary Pattern, Mild Cognitive Impairment, and Progression to Dementia. Archives of Neurology, 2009, 66, 910.	4.5	5
299	The Multidimensional Prognostic Index (MPI), Based on a Comprehensive Geriatric Assessment Predicts Short- and Long-Term Mortality in Hospitalized Older Patients with Dementia. Journal of Alzheimer's Disease, 2009, 18, 191-199.	2.6	77
300	Moderate Alcohol Consumption, Apolipoprotein E, and Neuroprotection. Archives of Neurology, 2009, 66, 538.	4.5	17
301	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1094-1099.	21.4	2,155
302	Role of Biphosphonates and Lymphatic Drainage Type Leduc in the Complex Regional Pain Syndrome (Shoulderâ€™Hand Syndrome). Pain Medicine, 2009, 10, 179-185.	1.9	9
303	RESPONSE LETTER TO DR. MELO ET AL.. Journal of the American Geriatrics Society, 2009, 57, 180-181.	2.6	1
304	APOLIPOPROTEIN E, DEMENTIA, AND HUMAN LONGEVITY. Journal of the American Geriatrics Society, 2009, 57, 740-742.	2.6	7
305	POSSIBLE PREDICTORS OF VASCULAR COGNITIVE IMPAIRMENTâ€™NO DEMENTIA. Journal of the American Geriatrics Society, 2009, 57, 943-944.	2.6	3
306	Wholeâ€™Diet Approach: Working on a Criterion Validity for Ageâ€™Related Cognitive Decline and Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2009, 57, 1944-1946.	2.6	13

#	ARTICLE	IF	CITATIONS
307	Short-term Effects of High-Intensity Laser Therapy Versus Ultrasound Therapy in the Treatment of People With Subacromial Impingement Syndrome: A Randomized Clinical Trial. <i>Physical Therapy</i> , 2009, 89, 643-652.	2.4	154
308	Higher total cholesterol, cognitive decline, and dementia. <i>Neurobiology of Aging</i> , 2009, 30, 546-548.	3.1	18
309	Alpha-2-macroglobulin gene, oxidized low-density lipoprotein receptor-1 locus, and sporadic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1518-1520.	3.1	11
310	Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease. <i>Ageing Research Reviews</i> , 2009, 8, 214-236.	10.9	46
311	Disease-Modifying Approach to the Treatment of Alzheimer's Disease. <i>Drugs and Aging</i> , 2009, 26, 537-555.	2.7	80
312	Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: drugs targeting β -amyloid and tau protein. <i>Aging Clinical and Experimental Research</i> , 2009, 21, 386-406.	2.9	47
313	N-3 polyunsaturated fatty acids and statins in heart failure. <i>Lancet</i> , The, 2009, 373, 380.	13.7	0
314	Temporal Relationship between Depressive Symptoms and Cognitive Impairment: The Italian Longitudinal Study on Aging. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 899-911.	2.6	49
315	Acoustic analysis of swallowing sounds: A new technique for assessing dysphagia. <i>Journal of Rehabilitation Medicine</i> , 2009, 41, 639-645.	1.1	58
316	Possible Role of S-Adenosylmethionine, S-Adenosylhomocysteine, and Polyunsaturated Fatty Acids in Predementia Syndromes and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 467-470.	2.6	23
317	Alcohol Drinking, Cognitive Functions in Older Age, Predementia, and Dementia Syndromes. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 7-31.	2.6	98
318	Botulinum Toxin Type A in the Treatment of Focal Hand Dystonia After Surgical Treatment for Thumb Duplication. <i>Orthopedics</i> , 2009, 32, 529.	1.1	2
319	Botulinum Toxin Type A in the Treatment of Painful Adductor Muscle Contracture After Total Hip Arthroplasty. <i>Orthopedics</i> , 2009, 32, .	1.1	8
320	Vascular risk factors, alcohol intake, and cognitive decline. <i>Journal of Nutrition, Health and Aging</i> , 2008, 12, 376-381.	3.3	29
321	Dietary fatty acids, age-related cognitive decline, and mild cognitive impairment. <i>Journal of Nutrition, Health and Aging</i> , 2008, 12, 382-386.	3.3	46
322	Impact of depressive symptoms on the rate of progression to dementia in patients affected by mild cognitive impairment. The Italian Longitudinal Study on Aging. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 726-734.	2.7	62
323	BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SIALORRHEA IN PARKINSON'S DISEASE. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 765-767.	2.6	21
324	BEYOND CORONARY ARTERY DISEASE: ROSUVASTATIN IN OLDER PATIENTS WITH ISCHEMIC SYSTOLIC HEART FAILURE. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 1366-1367.	2.6	2

#	ARTICLE	IF	CITATIONS
325	MILD COGNITIVE IMPAIRMENT: DEMENTIA RISK FACTOR OR HIGH-RISK STATE FOR PROGRESSION TO DEMENTIA?. Journal of the American Geriatrics Society, 2008, 56, 1367-1369.	2.6	3
326	Lifestyle-related factors in predementia and dementia syndromes. Expert Review of Neurotherapeutics, 2008, 8, 133-158.	2.8	129
327	Depressive Symptoms, Vascular Risk Factors and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2008, 25, 336-346.	1.5	38
328	Short arm of chromosome 11 and sporadic Alzheimer's disease: Catalase and cathepsin D gene polymorphisms. Neuroscience Letters, 2008, 432, 237-242.	2.1	18
329	Polymorphism C in the serotonin transporter gene (SLC6A4) in questionable dementia and Alzheimer's disease. Neuroscience Letters, 2008, 438, 335-339.	2.1	10
330	S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in predementia syndromes and Alzheimer's disease. Neurobiology of Aging, 2008, 29, 478-480.	3.1	4
331	Hypertension and Mild Cognitive Impairment Subtypes. Archives of Neurology, 2008, 65, 992.	4.5	6
332	Association Analysis of <i>GRIN2B</i> , Encoding N-Methyl-D-Aspartate Receptor 2B Subunit, and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2008, 25, 287-292.	1.5	20
333	Alcohol Use, Thiamine Deficiency, and Cognitive Impairment. JAMA - Journal of the American Medical Association, 2008, 299, 2853.	7.4	12
334	The RELN Locus in Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 335-344.	2.6	56
335	Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: A case for switching therapy?. Journal of Rehabilitation Medicine, 2008, 40, 882-883.	1.1	4
336	EFFECT OF A CLINICAL STROKE ON THE RISK OF DEMENTIA IN A PROSPECTIVE COHORT. Neurology, 2007, 68, 1748-1749.	1.1	0
337	Mild cognitive impairment: Risk of Alzheimer disease and rate of cognitive decline. Neurology, 2007, 68, 964-965.	1.1	8
338	Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology, 2007, 68, 1238-1239.	1.1	1
339	CIND AND MCI IN THE ITALIAN ELDERLY: FREQUENCY, VASCULAR RISK FACTORS, PROGRESSION TO DEMENTIA. Neurology, 2007, 69, 2186-2187.	1.1	53
340	Progression to Dementia in Probable and Possible Mild Cognitive Impairment. Archives of Neurology, 2007, 64, 1209.	4.5	2
341	Alcohol consumption, mild cognitive impairment, and progression to dementia. Neurology, 2007, 68, 1790-1799.	1.1	133
342	Whole-Diet Approach, Mediterranean Diet, and Alzheimer Disease. Archives of Neurology, 2007, 64, 606.	4.5	6

#	ARTICLE	IF	CITATIONS
343	Apolipoprotein E Genotypes in Hospitalized Elderly Patients with Vascular Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 327-333.	1.5	26
344	Incident Occurrence of Depressive Symptoms among Patients with Mild Cognitive Impairment â€” The Italian Longitudinal Study on Aging. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 55-64.	1.5	66
345	Heterogeneity of mild cognitive impairment and other predementia syndromes in progression to dementia. <i>Neurobiology of Aging</i> , 2007, 28, 1631-1632.	3.1	23
346	Lipoproteins, Vascular-Related Genetic Factors, and Human Longevity. <i>Rejuvenation Research</i> , 2007, 10, 441-458.	1.8	25
347	Differences in allele frequencies of ACE I/D polymorphism between Northern and Southern Europe at different ages. <i>Atherosclerosis</i> , 2007, 193, 455-457.	0.8	6
348	Possible Role of Unsaturated Fatty Acids in a 14-Day Healthy Longevity Lifestyle Program. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 266.	1.2	4
349	TOTAL CHOLESTEROL LEVELS AND THE RISK OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 133-135.	2.6	15
350	DIETARY POLYUNSATURATED FATTY ACID SUPPLEMENTATION, PREDEMENTIA SYNDROMES, AND ALZHEIMER'S DISEASE. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 469-470.	2.6	9
351	CHANGE OF DIAGNOSES IN PROBABLE AND POSSIBLE MILD COGNITIVE IMPAIRMENT: THE ITALIAN LONGITUDINAL STUDY ON AGING. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1480-1482.	2.6	2
352	LIFESTYLE-RELATED FACTORS, ALCOHOL CONSUMPTION, AND MILD COGNITIVE IMPAIRMENT. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1679-1681.	2.6	11
353	The Missing ApoE Allele. <i>Annals of Human Genetics</i> , 2007, 71, 496-500.	0.8	21
354	Interleukin 6 Variable Number of Tandem Repeats (VNTR) Gene Polymorphism in Centenarians. <i>Annals of Human Genetics</i> , 2007, 71, 843-848.	0.8	13
355	Mediterranean diet, mild cognitive impairment, and Alzheimer's disease. <i>Experimental Gerontology</i> , 2007, 42, 6-7.	2.8	22
356	Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline. <i>Aging Clinical and Experimental Research</i> , 2006, 18, 144-148.	2.9	17
357	Efficacy and tolerability of combined treatment with l-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. <i>Atherosclerosis</i> , 2006, 188, 455-461.	0.8	42
358	Circulating biomarkers of cognitive decline and dementia. <i>Clinica Chimica Acta</i> , 2006, 364, 91-112.	1.1	124
359	Nutritional factors, cognitive decline, and dementia. <i>Brain Research Bulletin</i> , 2006, 69, 1-19.	3.0	83
360	Cognitive frailty: Predementia syndrome and vascular risk factors. <i>Neurobiology of Aging</i> , 2006, 27, 933-940.	3.1	140

#	ARTICLE	IF	CITATIONS
361	Current knowledge of chromosome 12 susceptibility genes for late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1537-1553.	3.1	22
362	Dietary intake of unsaturated fatty acids and age-related cognitive decline: A 8.5-year follow-up of the Italian Longitudinal Study on Aging. <i>Neurobiology of Aging</i> , 2006, 27, 1694-1704.	3.1	222
363	Macronutrients, aluminium from drinking water and foods, and other metals in cognitive decline and dementia. <i>Journal of Alzheimer's Disease</i> , 2006, 10, 303-330.	2.6	44
364	Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism. <i>Vascular Disease Prevention</i> , 2006, 3, 235-245.	0.2	0
365	PREVALENCE RATES OF MILD COGNITIVE IMPAIRMENT SUBTYPES AND PROGRESSION TO DEMENTIA. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1474-1475.	2.6	3
366	DIET, CHOLESTEROL METABOLISM, AND ALZHEIMER'S DISEASE: APOLIPOPROTEIN E AS A POSSIBLE LINK?. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1963-1965.	2.6	9
367	WHOLE-FOOD DIET APPROACH AND RISK OF CHRONIC DISEASE: LIMITS AND ADVANTAGES. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1800-1802.	2.6	19
368	APOLIPOPROTEIN E GENOTYPES IN MILD COGNITIVE IMPAIRMENT SUBTYPES. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1965-1966.	2.6	11
369	Dietary fatty acids intakes and rate of mild cognitive impairment. The Italian Longitudinal Study on Aging. <i>Experimental Gerontology</i> , 2006, 41, 619-627.	2.8	75
370	Serum total cholesterol as a biomarker for Alzheimer's disease: Mid-life or late-life determinations?. <i>Experimental Gerontology</i> , 2006, 41, 805-806.	2.8	14
371	Cardiovascular Factors and Cognitive Impairment: A Role for Unsaturated Fatty Acids and Mediterranean Diet?. <i>American Journal of Cardiology</i> , 2006, 98, 1120-1121.	1.6	7
372	Lipid metabolism in cognitive decline and dementia. <i>Brain Research Reviews</i> , 2006, 51, 275-292.	9.0	165
373	Candidate genes for late-onset Alzheimer's disease: Focus on chromosome 12. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 36-47.	4.6	16
374	Adherence to a Mediterranean dietary pattern and risk of Alzheimer's disease. <i>Annals of Neurology</i> , 2006, 60, 620-620.	5.3	13
375	Low incidence for predementia and dementia syndromes in a brain imaging study. <i>Annals of Neurology</i> , 2006, 60, 619-619.	5.3	0
376	Sex Differences in the Association of Apolipoprotein E and Angiotensin-Converting Enzyme Gene Polymorphisms With Healthy Aging and Longevity: A Population-Based Study From Southern Italy. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2006, 61, 918-923.	3.6	70
377	Stroke and Memory Decline: A Question of Degenerative or Vascular Origin. <i>Archives of Neurology</i> , 2006, 63, 1347.	4.5	1
378	Dietary fatty acids intake: possible role in cognitive decline and dementia. <i>Experimental Gerontology</i> , 2005, 40, 257-270.	2.8	113

#	ARTICLE	IF	CITATIONS
379	Unsaturated fatty acids intake and all-causes mortality: a 8.5-year follow-up of the Italian Longitudinal Study on Aging. <i>Experimental Gerontology</i> , 2005, 40, 335-343.	2.8	33
380	Polymorphisms in the Oxidized Low-Density Lipoprotein Receptor-1 Gene and Risk of Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 280-284.	3.6	20
381	Molecular Determinants of Human Longevity. <i>Advances in Clinical Chemistry</i> , 2005, 39, 185-210.	3.7	1
382	The Cathepsin D Gene Exon 2 (C224T) Polymorphism and Sporadic Alzheimer's Disease in European Populations. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 991-996.	3.6	14
383	Current Epidemiology of Mild Cognitive Impairment and Other Predementia Syndromes. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 633-644.	1.2	171
384	Italian Project on Epidemiology of Alzheimer's disease (I.P.R.E.A.): study design and methodology of cross-sectional survey. <i>Aging Clinical and Experimental Research</i> , 2005, 17, 29-34.	2.9	18
385	Current Epidemiology of Mild Cognitive Impairment and Other Predementia Syndromes. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 633-644.	1.2	109
386	Vascular risk factors, incidence of MCI, and rates of progression to dementia. <i>Neurology</i> , 2004, 63, 1882-1891.	1.1	482
387	Mediterranean diet and cognitive decline. <i>Public Health Nutrition</i> , 2004, 7, 959-963.	2.2	173
388	Vascular genetic factors and human longevity. <i>Mechanisms of Ageing and Development</i> , 2004, 125, 169-178.	4.6	37
389	Interleukin 6 -174 G/C promoter gene polymorphism in centenarians: no evidence of association with human longevity or interaction with apolipoprotein E alleles. <i>Experimental Gerontology</i> , 2004, 39, 1109-1114.	2.8	35
390	Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe. <i>Experimental Gerontology</i> , 2004, 39, 1567-1573.	2.8	63
391	Vascular risk and genetics of sporadic late-onset Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2004, 111, 69-89.	2.8	60
392	Regional European differences in allele and genotype frequencies of low density lipoprotein receptor-related protein 1 polymorphism in Alzheimer's disease. <i>American Journal of Medical Genetics Part A</i> , 2004, 126B, 69-73.	2.4	19
393	Angiotensin I converting enzyme (ACE) gene polymorphism in centenarians: Different allele frequencies between the North and South of Europe. <i>Experimental Gerontology</i> , 2003, 38, 1015-1020.	2.8	66
394	Shifts in angiotensin I converting enzyme insertion allele frequency across Europe: implications for Alzheimer's disease risk. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1159-1161.	1.9	29
395	Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians. <i>NeuroReport</i> , 2003, 14, 605-608.	1.2	52
396	Semantic Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 695-696.	1.2	0

#	ARTICLE	IF	CITATIONS
397	Semantic Dementia: Neuropsychological and Behavioral Patterns in Relation to Hemispheric Asymmetries. American Journal of Geriatric Psychiatry, 2003, 11, 695-696.	1.2	2
398	F175S Change and a Novel Polymorphism in Presenilin-1 Gene in Late-Onset Familial Alzheimer's Disease. European Neurology, 2002, 47, 209-213.	1.4	10
399	Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 732-736.	1.9	81
400	Selective Attention Skills in Differentiating between Alzheimer's Disease and Normal Aging. Journal of Geriatric Psychiatry and Neurology, 2002, 15, 99-109.	2.3	24
401	Relation of lipoprotein(a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients ≥65 years of age (The Italian Longitudinal Study on Aging). American Journal of Cardiology, 2002, 89, 825-829.	1.6	37
402	Lipoprotein(a) in the elderly: beyond atherosclerosis. Archives of Gerontology and Geriatrics, 2002, 35, 337-343.	3.0	0
403	Serum apolipoprotein E levels in Alzheimer's disease and extreme longevity. Archives of Gerontology and Geriatrics, 2002, 35, 345-352.	3.0	5
404	Lack of association between APOE polymorphism and Alzheimer's disease in southern Italy. Archives of Gerontology and Geriatrics, 2002, 35, 239-245.	3.0	8
405	Apolipoprotein and angiotensin converting enzyme genes: regional differences and extreme longevity in Europe. Archives of Gerontology and Geriatrics, 2002, 35, 247-251.	3.0	4
406	Impact of decreased frequency of apolipoprotein E ε4 allele on Alzheimer's disease in Southern Italy. Archives of Gerontology and Geriatrics, 2001, 33, 299-306.	3.0	1
407	Analysis of individual items of mini-mental state examination in discrimination between normal and demented subjects. Archives of Gerontology and Geriatrics, 2001, 33, 357-362.	3.0	8
408	Apolipoprotein E in Southern Italy: protective effect of ε2 allele in early- and late-onset sporadic Alzheimer's disease. Neuroscience Letters, 2000, 292, 79-82.	2.1	39
409	Decreased frequency of apolipoprotein E ε4 allele from Northern to Southern Europe in Alzheimer's disease patients and centenarians. Neuroscience Letters, 1999, 277, 53-56.	2.1	75
410	Efficacy of Cytidine Diphosphate Choline in Patients Affected by Chronic Cerebrovascular Disease. Clinical Drug Investigation, 1996, 12, 26-38.	2.2	8
411	Non-Pharmacological Approaches in the Treatment of Dementia. , 0, , .		3